The Suboxone class action lawsuit, centered on allegations that the opioid addiction treatment drug Suboxone causes severe dental problems, continues to advance significantly in 2025. Patients worldwide have joined the multidistrict litigation (MDL) against Indivior Inc. and other manufacturers, claiming that the drug’s acidic sublingual film formulation led to extensive tooth decay, enamel erosion, and irreversible oral injuries, for which proper warning was delayed or insufficient.
Background of the Suboxone Lawsuit
Approved by the FDA for opioid use disorder, Suboxone is administered as a dissolvable film placed under the tongue. Plaintiffs allege that this film’s high acidity damages dental enamel over time, even with good oral hygiene. The manufacturers are accused of concealing these risks, failing to provide adequate warnings until the FDA mandated label updates in mid-2022.
Since then, nearly 900 cases have been consolidated in MDL No. 3092, filed in the Northern District of Ohio under Judge J. Philip Calabrese’s supervision.
Key Developments in 2025
- Increased Case Numbers: The number of cases steadily rose from about 700 in early 2025 to nearly 900 by July, indicating expanding awareness and participation by victims experiencing dental harm.
- Leadership Reappointed: Plaintiffs’ counsel leadership was extended through June 2026, providing consistent guidance in managing the complex litigation efficiently.
- Document and Evidence Collection: Recent case management orders require pharmacies nationwide to produce prescription records within 30 days to substantiate claims and strengthen case evidence.
- Bilateral Depositions: Depositions of Indivior and other defendants’ executives have begun, focusing on internal knowledge of dental risks, marketing practices, and timing of warning labels.
- Bellwether Trial Preparation: The court outlined procedures for selecting test cases that will proceed to early trial, influencing potential settlement negotiations and case outcomes.
Legal Claims and Plaintiff Allegations
Plaintiffs assert several critical claims:
- Failure to Warn: Defendants did not disclose the significant dental risks of Suboxone films despite knowing about acid-related tooth damage documented as early as the mid-2000s.
- Design Defect: The film’s formulation is alleged to be inherently dangerous compared to injectable or alternative treatments lacking similar harmful dental effects.
- Fraud and Misrepresentation: Defendants marketed Suboxone as safe while deliberately omitting or minimizing dental risk information.
- Damages: Plaintiffs seek compensation for extensive dental surgeries, emotional distress, lost wages, and diminished quality of life.
Current Status and Future Outlook
The litigation remains active with no settlement reached as of mid-2025. Key trials are anticipated later in the year, which will be critical in testing the strength of claims and influencing further resolution.
Lawyers caution potential plaintiffs about evidentiary requirements, urging documentation of dental damage and Suboxone usage to bolster claims.
What Plaintiffs Should Know
- If you have used Suboxone and experienced dental issues, consider legal consultation to evaluate your eligibility for the class action.
- Preserve detailed dental and medical records documenting the injury and its progression.
- Keep prescription and pharmacy records relating to Suboxone purchases and usage.
- Stay updated with legal notices and procedural deadlines to protect your rights.
Conclusion
The Suboxone class action lawsuit continues to be a pivotal legal matter addressing pharmaceutical accountability and patient safety. It underscores the importance of timely warnings, transparent drug marketing, and equitable compensation for those harmed by medication side effects.
As the litigation progresses, it serves as a landmark case in product liability law, balancing patient interests against drug company defenses and regulatory standards.
